An interventional study of Transpalpebral microcurrent electrical stimulation in Age-Related Macular Degeneration (AMD), sponsored by Clarity Eye Institute. Not yet recruiting at 3 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Clarity Eye Institute · Not applicable, Interventional, and Treatment
Age-related macular degeneration (AMD) is an eye condition that affects the retina and can lead to progressive vision loss. This study will evaluate the effects of MacuMira microcurrent stimulation on dark adaptation in adults with intermediate dry AMD.
Participants will receive four in-office treatment sessions over 10 to 14 days. Dark adaptation and other measures of visual function and retinal health will be assessed before treatment and at one and three months after treatment.
1,459 studies on the registry are indexed under Macular Degeneration; 238 are open to participants now.
This study's planned enrollment of 50 is below the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Browse Macular Degeneration studies →Clarity Eye Institute is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants will receive four in-office sessions of transpalpebral microcurrent electrical stimulation using the MacuMira device over approximately 10 to 14 days.
Device: Transpalpebral microcurrent electrical stimulation
Four in-office sessions of transpalpebral microcurrent electrical stimulation using the MacuMira device. The first treatment session will occur within 7 days of screening/baseline, with the remaining sessions administered over approximately 10 to 14 days.
Change in Rod Intercept Time (RIT) from Baseline to Month 1
Change in RIT, measured using the AdaptDx Pro dark adaptation test, from the average of two baseline assessments to the single RIT assessment at Month 1. The two baseline measurements will be obtained at the Screening/Baseline visit and Treatment Day 1, prior to the first MacuMira treatment, and averaged to establish baseline RIT. Each eligible eye will be assessed separately.
Time frame: Average of two baseline assessments (Screening/Baseline and Treatment Day 1) to the single assessment at Month 1.
Change in Rod Intercept Time (RIT) from Baseline to Month 3
Change in RIT, measured using the AdaptDx Pro dark adaptation test, from the average of two baseline assessments to the single RIT assessment at Month 3. Each eligible eye will be assessed separately.
Time frame: Average of two baseline assessments (Screening/Baseline and Treatment Day 1) to the single assessment at Month 3.
Change in Best-Corrected Visual Acuity (BCVA)
Change in BCVA, measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart, from baseline to Month 1 and Month 3.
Time frame: Baseline to the single assessment at Month 1 and the single assessment at Month 3.
Change in Contrast Sensitivity
Change in contrast sensitivity, measured using the Pelli-Robson chart, from baseline to Month 1 and Month 3.
Time frame: Baseline to the single assessment at Month 1 and the single assessment at Month 3.
Change in Low Luminance Deficit (LLD)
Change in LDD from baseline to the single assessment at Month 1 and the single assessment at Month 3.
Time frame: Baseline to the single assessment at Month 1 and the single assessment at Month 3.
Change in Vision-Related Quality of Life
Change in vision-related quality of life, measured using the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25), from baseline to the single assessment at Month 1 and the single assessment at Month 3.
Time frame: Baseline to the single assessment at Month 1 and the single assessment at Month 3.
Retinal Anatomic Stability Assessed by Optical Coherence Tomography (OCT)
Assessment of retinal anatomic stability using OCT, including changes in macular thickness and macular volume, from baseline to Month 1 and Month 3.
Time frame: Baseline to the assessment at Month 1 and the assessment at Month 3.
Changes in Fundus Autofluorescence (FAF)
Assessment of changes in retinal appearance using FAF imaging from baseline to Month 1 and Month 3.
Time frame: Baseline to the assessment at Month 1 and the assessment at Month 3.
Plan to share: No
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Clarity Eye Institute